Related by context. All words. (Click for frequent words.) 80 Forced Vital 67 ACR# responses 65 Pharmacokinetic parameters 65 -#.# mg dL [001] 64 ACR# response 64 baseline HbA1c 64 baseline FEV 64 R# #mg BID 64 Index CDAI 64 Crohn Disease Activity 63 ADCS CGIC 63 Hb A1C 63 Kaplan Meier estimates 62 serologically active patients 62 Endocrine Therapy 62 Platelet counts 62 oxycodone CR 62 trough FEV1 62 PASI scores 62 MADRS score 62 HBeAg seroconversion 62 baseline serum creatinine 62 albumin excretion rate 62 HOMA IR 62 Score IPSS 62 CDAI score 62 ACR# ACR# 61 RECIST Response Evaluation Criteria 61 fasting plasma glucose FPG 61 sustained virological response 61 clinically meaningful improvement 61 EDSS scores 61 Scale cognitive subscale 61 cEVR 61 hematological parameters 61 Viral load 61 baseline FEV1 61 IPSS 61 HAQ DI 60 CIN3 60 International Prostate Symptom 60 urine NGAL 60 PREZISTA r arm 60 alanine aminotransferase ALT 60 CR nPR 60 mg BID dose 60 PSADT 60 MCyR 60 Expanded Disability Status 60 ALT elevation 60 Prostate Cancer Recurrence 60 myocardial viability 60 Montgomery Asberg Depression 60 spirometric 60 Ejection Fraction 60 Psoriasis Area 60 virologic response 60 Employee Confidence 60 PSA nadir 60 adenoma recurrence 60 echocardiographic parameters 60 confirmed CCyR 60 bortezomib refractory 60 HbA 1c levels 60 HER2 expression 60 Bankruptcy Filings Up 59 log# copies mL 59 Proteinuria 59 virological response 59 morphometric vertebral fractures 59 complete cytogenetic response 59 gadolinium enhancing lesions 59 follicular lymphomas 59 Gastrointestinal Stromal Tumors 59 aspartate aminotransferase AST 59 annualized relapse 59 SVR# 59 Scale EDSS score 59 Predictive Value 59 Cardiotoxicity 59 ADAS Cog 59 Newly Diagnosed Patients 59 Kaplan Meier analysis 59 Brief Psychiatric 59 Scale EDSS 59 estimated GFR 59 lumbar spine BMD 59 Partial Response 59 calculated creatinine clearance 59 CIMZIA ™ 59 Oral Fingolimod 59 univariate analyzes 59 6MWD 59 neuropathy sensory 59 Non inferiority 59 Alzheimer Disease Assessment 58 -#.# log# 58 Skin sterol 58 Functional Outcomes 58 ANCOVA 58 Cystatin C 58 glycated hemoglobin HbA1c 58 Response Evaluation Criteria 58 virologic responses 58 Relapsing Remitting Multiple Sclerosis 58 ADAS cog 58 glycosylated hemoglobin HbA1c 58 hip BMD 58 Main Outcome Measure 58 Treatment Outcome 58 biochemical relapse 58 prospectively defined 58 -#.# mg dL [002] 58 exploratory endpoints 58 Breast Carcinoma 58 STRATEGY FOR AN OPEN 58 Fasting blood glucose 58 odds ratios ORs 58 Negative Symptoms 58 weekly CSBMs 58 glycated hemoglobin levels 58 SCr 58 Dyspnea 58 MARINOL R 58 mL/min/#.# m 2 58 Primary Endpoint 58 univariate 58 elevated ALT 58 sensitivity specificity 58 Aggressive Prostate Cancer 58 Heart Failure Therapies 58 azilsartan medoxomil 58 preintervention 58 CIBIC plus 58 aminotransferase ALT 58 relapsed MM 58 Jobless Claims Climb 57 PSA kinetics 57 ACTEMRA TM 57 pharmacokinetic PK profile 57 extrapyramidal symptoms 57 prospectively stratified 57 Coronary Artery Calcium 57 STRIDE PD 57 SUVmax 57 multivariate adjustment 57 IBDQ 57 PRADAXA #mg 57 Primary endpoints 57 % Confidence Interval 57 posttreatment 57 FEV ^ sub 57 BENICAR HCT 57 moderate renal impairment 57 pulmonary capillary wedge 57 hemoglobin A1C HbA1C 57 DAS# CRP 57 lopinavir r arm 57 Hyperlipidemia 57 HbA1C 57 mTSS 57 NNT = 57 receiving golimumab 57 nonfasting triglyceride levels 57 Secondary Endpoints 57 hemoglobin A1c levels 57 serum estradiol 57 prednisone prednisolone plus 57 Negative Syndrome 57 DAS# scores 57 YMRS 57 hematologic parameters 57 arterial thickening 57 affective psychosis 57 Masimo PVI 57 ARB telmisartan 57 EBMT criteria 57 hemoglobin A1c HbA1c 57 Mortality Risk 57 multivariate logistic regression 57 Score TOS 57 cytogenetic response 57 Albuminuria 57 Nesiritide 57 oral FTY# 57 platelet reactivity 57 CIN2 + 57 EDSS score 57 multivariable adjusted 57 abdominal adiposity 57 generalized edema 57 HBeAg 57 oxygen desaturation 57 confidence intervals CIs 57 CP CPPS 57 Lung Cancer Survival 57 EMBLEM TM 57 baseline LDH 57 Prostate Cancer Progression 57 anemia hemoglobin 57 fasting insulin 56 Hemoglobin A1c 56 Wholesale Inventories Rise 56 Breast Density 56 baseline A1C 56 Texas Instruments Narrows 56 Prognostic Value 56 Subgroup analysis 56 alanine aminotransferase 56 tipranavir r 56 Pharmacokinetic 56 HAM D# scores 56 SPIRIT FIRST 56 Fibromyalgia Pain 56 Prostate Cancer Survival 56 Descriptive statistics 56 fasting plasma glucose 56 subscore 56 Sleep Disturbance 56 cTnT levels 56 serum HBV DNA 56 CCyR 56 SELENA SLEDAI score 56 Subgroup analyzes 56 Endothelial function 56 Available Seat Kilometres ASKs 56 Levels Linked 56 HbA 1C 56 Metastatic Renal Cell Carcinoma 56 Showed Significant 56 Neuroticism 56 Idenix Pharmaceuticals Reports 56 Lupus Drug 56 Quantifiable 56 8mg/kg 56 DAS# remission 56 Rosenberg Self Esteem 56 Symptom severity 56 Outpatient Setting 56 ACR Pedi 56 intact parathyroid hormone 56 XIENCE V PROMUS Stent 56 overt nephropathy 56 Respiratory Symptoms 56 Univariate 56 microbiological eradication 56 autonomic dysfunction 56 Clinical Outcomes Utilizing Revascularization 56 Secondary endpoints 56 postintervention 56 liver histology 56 NIHSS score 56 Severity Index PASI 56 TLUS 56 Jobless Claims Dip 56 timepoint 56 SLE Responder Index 56 plus MTX 56 Main Outcome Measures 56 HDL Cholesterol 56 Sleep Disturbances 56 response CCyR 56 MMSE score 56 Negative Symptom Scale PANSS 56 Scale Cognitive Subscale 56 thrombosis embolism 56 creatinine ratio 56 urinary calcium excretion 56 LV dysfunction 56 Drug Prevents 56 QTcF 56 UPDRS scores 56 Renal Cell Carcinoma RCC 56 secondary efficacy endpoints 56 Depressive Symptoms 56 definite stent thrombosis 56 serum creatinine levels 56 Pooled Analysis 56 Androgen Deprivation 56 WOMAC pain 56 Solid Tumors RECIST 56 HBeAg negative patients 56 Statistically Significant 56 placebo fluoxetine 56 serum phosphate 56 Genes Predict 56 postdose 56 peg interferon 56 serum clusterin levels 56 Fibromyalgia Impact Questionnaire 56 Univariate analysis 56 metabolite concentrations 56 Localized Prostate Cancer 56 serum urate levels 56 postoperative pulmonary 56 Hemodialysis Patients 56 p = NS 56 viral kinetics 56 undetectable HCV RNA 56 Flu Cy 56 Demonstrated Significant 56 sUA 56 Spherion Employee Confidence Index 56 coronary calcification 56 Mortgage Rates Climb 56 #mg dose [002] 56 postoperative mortality 56 FOR AN OPEN 56 RESIST studies 56 HSCT 56 venlafaxine XR 56 CPAP adherence 56 #F FDG PET 56 Telik Announces 55 Hypotension 55 Atopic Dermatitis 55 Dose Escalation 55 OGTT 55 Severity MSCS score 55 univariate analysis 55 PegIFN RBV 55 UACR 55 Cardiorespiratory fitness 55 arterial thromboembolic events 55 Ocular Surface Disease 55 evaluable subjects 55 HORIZONS AMI trial 55 Heart Failure Patients 55 Elastography 55 undetectable HBV DNA 55 Annualized ROE 55 Gene Variation 55 covariance ANCOVA 55 Logistic regression 55 serum potassium 55 Complete Remission 55 multivariate analyzes 55 Angiographic 55 serum parathyroid hormone 55 Hepatitis C Antiviral 55 Prostate specific antigen 55 nonfatal myocardial infarction 55 Virologic failure 55 GAMMAGARD 55 Colorectal Cancers 55 Cystic Fibrosis Questionnaire Revised 55 REYATAZ r arm 55 BPRS PSS 55 hsCRP levels 55 subclinical atherosclerosis 55 biochemical recurrence 55 symptomatic VTE 55 Atkins dieters cardiovascular 55 mcg QD 55 Clinical Outcome 55 mean baseline A1C 55 mcg BID 55 CIMZIA TM certolizumab pegol 55 logistic regression analysis 55 lipoprotein Lp 55 SGOT 55 SF #v# 55 solifenacin 55 achieved ACR# 55 Latest WeatherWatch 4 55 elevated serum creatinine 55 Hepatotoxicity 55 CSF biomarkers 55 Ishak fibrosis score 55 intravascular hemolysis 55 Adenomas 55 meta regression 55 Geriatric Depression 55 Cardiac Biomarkers 55 rosuvastatin #mg 55 estimated glomerular filtration 55 PREZISTA ritonavir 55 microalbuminuria 55 Patient Outcomes 55 multiple logistic regression 55 urine albumin 55 Neoadjuvant Chemotherapy 55 Microalbuminuria 55 Relapsing Multiple Sclerosis 55 Virologic 55 RECIST criteria 55 ADCS ADL 55 depressive symptom 55 posttransplant 55 Treatment Naive Patients 55 cardiac dysfunction 55 Demonstrate Significant 55 Hematologic 55 See CLINICAL PHARMACOLOGY 55 FEV1 55 Hematocrit 55 Pain Intensity 55 antiretroviral naïve 55 intima media thickness 55 exhaled NO 55 serum aminotransferase levels 55 Sustained virologic response 55 serum testosterone 55 clinically meaningful reductions 55 HbA1C levels 55 NLX P# 55 Lipstick Mystic Love 55 desvenlafaxine succinate 55 Fecal Incontinence 55 Arterial stiffness 55 alicaforsen enema 55 SGPT 55 FluCAM arm 55 Kaplan Meier curve 55 CYP#A# substrate 55 Septic Shock 55 seropositivity 55 Secondary efficacy endpoints 55 Significant Improvements 55 Currency Majors Technical 55 Hormone Receptor Positive 55 Treated Patients 55 multivariate Cox 55 Kaplan Meier method 55 CIMZIA TM 55 fullyear outturn represents 55 Mortgage Rates Decline 55 Inflammatory Markers 55 euthymic patients 55 resected pancreatic cancer 55 NIHSS 55 binary restenosis 55 secondary efficacy endpoint 55 Laryngeal Cancer 55 FDA defined valvulopathy 55 Depressive symptoms 55 ORAL Solo 55 Endothelial Function 55 fosamprenavir 55 glycosylated hemoglobin 55 Sociodemographic 55 Pharmacodynamic 55 macroalbuminuria 55 CVD mortality 55 specific antigen PSA 55 multivariable analyzes 55 dapagliflozin plus 55 Visual acuity 55 Physical Function 55 achieved CCyR 55 Montgomery Åsberg Depression 55 atherogenic dyslipidemia 55 mean ± SEM 55 serum lipid levels 55 angiographic outcomes 55 Cause Mortality 55 Statistically Significant Improvement 54 NMIBC 54 AUA Symptom Score 54 Kaplan Meier 54 Rating Scale MADRS 54 Cholinesterase Inhibitors 54 Ameris Bancorp Reports 54 PCWP 54 Exacerbations 54 graft dysfunction 54 #OHD levels 54 KRAS status 54 Vehicle Dependability 54 FOLPI 54 Housing Starts Plunge 54 plasma HCV RNA 54 HAMD 54 advanced adenoma 54 bivariate 54 Genetic Variants 54 Logistic regression analysis 54 glomerular filtration 54 SIMPADICO 54 serum urate 54 BENICAR 54 Unified Parkinson Disease 54 Patients Receiving 54 sustained virologic response 54 aminotransferases 54 Therapy Reduces 54 HER2 overexpression 54 Decompensated Heart Failure 54 generalized estimating 54 HOXB# 54 ASCUS 54 FACIT Fatigue 54 glomerular filtration rate 54 quetiapine XR 54 Doxil ® 54 AST ALT 54 creatinine levels 54 lymphopenia 54 Wisconsin Sleep Cohort 54 ARCOXIA 54 log# reduction 54 homocysteine concentrations 54 cystatin C 54 glycated hemoglobin 54 certolizumab 54 APTIVUS r 54 Nonresidential Construction 54 logistic regression model 54 Virologic Response 54 LDL Cholesterol 54 RECORD1 54 Postoperative 54 waist circumference WC 54 FEV1 forced expiratory 54 Major Adverse Cardiac 54 aldosterone antagonist 54 Follicular Lymphoma 54 Coronary artery calcium 54 Fracture Risk 54 recurrent VTE 54 HBV DNA levels 54 albumin excretion 54 CARDIA 54 Natural Catastrophe Stress 54 NAbs 54 inflammatory biomarkers 54 Stent thrombosis 54 multivariable logistic regression 54 Nicotine Vaccine 54 mammographic density 54 YY =Anders Ostergaard 54 PANSS total 54 Jobless Claims Fell 54 Non Responders 54 artery stenosis 54 permanently discontinue Vectibix 54 hormone receptor status 54 Revises FY# 54 plus methotrexate 54 nonfasting triglycerides 54 AGILECT R 54 lactate dehydrogenase LDH 54 transaminases 54 Seasonally Adjusted Annualized 54 bronchial hyperresponsiveness 54 NIH CPSI 54 complete Early Virological 54 polyp recurrence 54 Uterine Cancer 54 PDP MLR 54 Household Penetration 54 mild renal insufficiency 54 Rheumatoid Arthritis Patients 54 apo B apo AI 54 Refinery utilization rebounded 54 HDRS 54 Jobless Claims Decline 54 virologic 54 plus dexamethasone 54 Jobless Claims Fall Sharply 54 logistic regression analyzes 54 angiographically 54 NWEA MAP 54 CombAT 54 PANSS scores 54 PROactive study 54 QTc prolongation 54 CANCIDAS 54 Free Survival PFS 54 Capsules CII 54 TNSS 54 median survivals 54 Hamilton Anxiety Scale 54 microalbumin 54 Breast Cancer Recurrence 54 carotid IMT 54 Visual Analogue Scale VAS 54 Opioid Use 54 intraobserver 54 Consumer Confidence Slips 54 iPTH 54 pharmacodynamic parameters 54 STN stimulation 54 FOLFOX4 54 eNO 54 serum PSA 54 Calcium Intake 54 Bone Metastases 54 Insulin Sensitivity 54 Breast Tissue 54 experienced virologic failure 54 MERIT ES 54 CLIRS 54 Morbidity Mortality 54 aspartate aminotransferase 54 sociodemographic characteristics 54 prospective multicentre 54 conditional logistic regression 54 blood Phe levels 54 Lipid Levels 54 Timed Walk 54 Metastatic Prostate Cancer 54 Mortgage Rates Dip 54 mRS 54 serum phosphorous 54 Median PFS 54 hemoglobin A1C 54 Study ARIC 54 prespecified secondary 54 Invasive Breast Cancer 54 CFQ R 54 aldosterone antagonists 54 DAS# [002] 54 elevated bilirubin 54 EUS FNA 54 Histologic 54 Pharmacogenetic 54 Wrestling Wrap Up 54 Cardiac Resynchronization 54 Tumor shrinkage 54 Adjuvant Treatment 54 System IPSS 54 Relapsed Multiple Myeloma 54 dose atorvastatin 54 SEISMIC Trial 54 MDRD 54 Grouped Hockey 54 laboratory abnormalities 54 Scale PANSS 54 Sexual Function 54 CRP marker 54 #-#,# mg 54 evaluating mipomersen 54 Psychosomatic Research 54 gp# vaccine 54 cytogenic 54 Acute Heart Failure 54 BPH Symptom Score 54 Prostate Cancer Risk 54 mcg albinterferon alfa 2b 54 Shows Modest 54 interindividual variability 54 Insulin sensitivity 54 CR CRu 54 PANSS Positive 54 severe exacerbations 54 ONGLYZA saxagliptin 54 postprocedure 54 Prognostic 54 Aromatase Inhibitors 54 Gender Disparity 54 Test Methodology 54 Maintains FY# 54 Folfox 54 ASCO GU 54 Repeatable Battery 54 transaminase elevations 53 DJ BTMU Business 53 concomitant medications 53 serum folate 53 Strongly Linked 53 NSTEMI 53 Renal Cell Carcinoma 53 tumor histology 53 bepotastine besilate nasal spray 53 Shows Efficacy 53 Acute Coronary Syndromes 53 aminotransferase levels 53 Global Impression CGI 53 Health Assessment Questionnaire 53 Rate ORR 53 Castration Resistant Prostate Cancer 53 TAXUS p value 53 multivariable Cox 53 neutropaenia 53 #.# Million Barrels [002] 53 nadroparin 53 mg BID 53 coronary stenosis 53 atherosclerotic renal artery stenosis 53 Lagging Indicators 53 Predict Risk 53 Orthostatic Hypotension 53 subclinical hypothyroidism 53 multivariable analysis 53 Risk Stratification 53 USD Minors USDCHF 53 Internationally EDC 53 carotid stenosis 53 Female Sexual Function 53 Tasigna prolongs 53 creatinine clearance 53 androgen depletion therapy 53 F FDG PET 53 Cardiovascular Disease Risk 53 Randomized Study 53 TIMP 1 53 CK MB 53 Japanese Stocks Climb 53 progression TTP 53 -#.# log# copies mL 53 adenotonsillectomy 53 Outcome Measures 53 clinically meaningful improvements 53 Multidetector CT 53 CYP#D# genotype 53 Month Avg 53 Backs FY# 53 Secondary endpoints included 53 plus OBT 53 PLX STROKE targeting 53 Functioning GAF 53 aged ≥ 53 Index CDAI score 53 detectable HCV RNA 53 FDG-PET/CT 53 atheroma volume 53 #illustrate how 53 HIV tropism 53 Cognitive Impairment 53 hypokalemia 53 Dialysis Outcomes 53 Genetic Defect 53 Productivity Rises 53 BARACLUDE r 53 serum CRP 53 Vasomotor Symptoms 53 androgen suppression 53 tapentadol ER 53 -5 -6 53 Wechsler Adult 53 fatigue asthenia 53 ritonavir boosted 53 peak VO2 53 suboptimal adherence 53 NSTE ACS 53 Help Predict 53 hepatic fibrosis 53 amisulpride 53 neurocognitive function 53 Inventory Levels 53 TDF FTC 53 serum vitamin D 53 dose proportionality 53 genotypic resistance 53 Multivariate analysis 53 unstable angina pectoris 53 Cognitive Function 53 Leading Indicators Rise 53 unfractionated heparin UFH 53 perioperative mortality 53 HbA 1c 53 Chronic HCV 53 Antitumor Activity 53 Ex Autos 53 BioSante Pharmaceuticals Reports 53 lymphocyte count 53 epoetin alpha 53 Rise Less Than 53 ASIA Impairment 53 MS relapses 53 serum IGF 53 Pervasive BI 53 Blood Clot Risk 53 Pediatric Patients 53 subscale scores 53 Platelet Counts 53 adefovir treated 53 Commended Performance 53 HIV RNA 53 5 Yr Avg 53 CDAI 53 CI -#.# 53 secondary endpoint 53 Jobless Rate Steady 53 fasting serum 53 FDG uptake 53 Arch Intern Med 53 Novel Inhibitor 53 repeat paracentesis 53 #.#ng/ml 53 Thrombocytopenia 53 p = .# [002] 53 ALT elevations 53 statistical significance p 53 International Prognostic Scoring 53 Forecast Predicts 53 pretest probability 53 dactylitis 53 infliximab monotherapy 53 vitreous haze 53 seropositive patients 53 Ischemic Stroke 53 Multiple logistic regression 53 ST Segment Elevation 53 Glomerular Filtration Rate 53 intermittent dosing 53 Significantly Improved 53 recurrent venous thromboembolism 53 Logistic Regression 53 ImmuKnow assay 53 scores TNSS 53 efficacy endpoint 53 familial AF 53 Lymph Nodes 53 Immunomedics Announces 53 â ‰ ¥ 53 Significant Improvement 53 virologic failure 53 DCE MRI 53 bronchopulmonary dysplasia BPD 53 transcranial Doppler ultrasound 53 Comorbidities 53 Systolic Blood Pressure 53 ‰ ¥ 53 Sensitivity specificity 53 nodular partial response 53 serum HCV RNA 53 Colorectal Cancer Patients 53 Multivariate logistic regression 53 Osteoporosis Drugs 53 sleeve lobectomy 53 serum uric acid 53 pulmonary exacerbation 53 Thrombolysis 53 rimonabant #mg 53 bivalirudin monotherapy 53 urinary N telopeptide 53 Diagnostic Criteria 53 First Patient Enrolled 53 C Reactive Protein 53 Combo Therapy 53 Dollar Sags 53 del 5q MDS 53 Renal Cancer 53 parkinsonian symptoms 53 death reinfarction 53 latest AAII Sentiment 53 ATACAND 53 Anticancer Activity 53 Munghana Lonene Listenership 53 Randomized Clinical Trials 53 deterministic nonlinear measure 53 LDH lactate dehydrogenase 53 Coronary Intervention 53 FOREXYARD Daily Forex 53 Survival Benefit 53 Study Demonstrates 53 Homocysteine levels 53 Renal Function 53 arterial oxygen saturation 53 % CI #.#-#.# [003] 53 serum thyroglobulin 53 lamivudine monotherapy 53 Hormone Refractory Prostate Cancer 53 Blood Glucose Testing 53 HCV antibody 53 Shows Promising 53 mU liter 53 AVweb Question 53 Interrater reliability 53 periprocedural 53 multiple linear regression 53 Glucose Metabolism 53 episodic migraine sufferers 53 Tumor Response 53 NHANES III 53 -#.# mmHg 53 mmHg diastolic 53 IL#B 53 Breast Tumors 53 Placebo Controlled Study 53 MADRS 53 TWYNSTA 53 confidence interval #.#-#.# 53 Affirms FY# 53 kilometers RPK 53 Echocardiographic 53 Pregnancy Complication 53 AUDUSD USDCAD 52 triglyceride concentrations 52 x ULN 52 logistic regression models 52 nonfatal MI 52 Entitlement Mentality 52 bivariate analysis 52 periprocedural MI 52 WOMAC TM 52 mucosal healing 52 clinically evaluable population 52 ptau 52 Contact Lens Wearers 52 T2 lesion volume 52 seroprotection 52 hemoglobin concentration 52 Bloodstream Infections 52 Statistical Significance 52 preoperative PSA 52 nondiabetic patients 52 Macroeconomic Confidence Index 52 Lung Cancer Risk 52 salivary cortisol 52 BMI z 52 multicenter multinational 52 Operative mortality 52 mITT population 52 pCR 52 Lp PLA 2 52 triiodothyronine 52 hypophosphatemia 52 mL sec 52 Intraocular pressure 52 Subarachnoid hemorrhage 52 Dyslipidemia 52 corticosteroid dose 52 systemic corticosteroid 52 Aortic stiffness 52 APOE genotype 52 Lowers FY# EPS 52 HBV infections 52 Smartphone Shipments 52 Lupuzor ™ 52 anti JCV antibodies 52 thyrotropin levels 52 postoperative complication 52 dosing cohort 52 WOMAC scores 52 Triglyceride levels 52 glycosylated hemoglobin levels 52 NYHA functional class 52 abnormal glucose metabolism 52 Rural Mainstreet economic 52 Study Evaluates 52 TAXUS Stent 52 NHANES #-# 52 leucopenia 52 CyberSecurity Solutions segment 52 corneal thickness 52 nonvertebral fractures 52 TEAEs 52 DLQI 52 Lowering Blood Pressure 52 Endothelial dysfunction 52 Mean Symptom Complex 52 ALSFRS R 52 N telopeptide 52 Juvenile Idiopathic Arthritis 52 methotrexate monotherapy 52 plasma renin activity 52 INTEGRILIN R eptifibatide Injection 52 Generalized Anxiety Disorder 52 Genetic Marker 52 pollster Ipsos Apoyo 52 Adjuvant Therapy 52 clinico pathological 52 ASCO Breast Cancer 52 hours postdose 52 squamous histology 52 β blockers 52 Adjuvant Chemotherapy 52 Opns 52 Sustained Virologic Response 52 inducible ischemia 52 Insulin Therapy 52 RRM1 52 HRQL 52 Nonalcoholic Fatty Liver Disease 52 Order Intake 52 stage IIIb IV 52 subjective sleepiness 52 left ventricular diastolic 52 FOLFIRINOX 52 Randomized Phase II 52 Randomized Double Blind 52 FOLFOX4 alone 52 APTIVUS 52 PSQI 52 Intermountain Risk Score 52 Fractional Flow Reserve 52 clinicopathological features 52 Backs FY# Revenue 52 % CI #.#-#.# [005] 52 HIV HCV coinfected 52 placebo dexamethasone 52 By JENNIFER LEARN 52 mucosal inflammation 52 p# biomarker 52 ECU netbacks 52 linaclotide treated 52 serum BDNF 52 Cardiopulmonary bypass 52 Bone Mineral Density 52 ADPKD 52 Psychometric tests 52 #q# deletion syndrome 52 ug kg 52 Disease Progression 52 urinary albumin 52 Electroencephalography